OBJECTIVE: The objective of this study was to investigate the mapping of sigma1 receptors in Parkinson's disease (PD) using [11C]SA4503 and positron emission tomography (PET), and to assess whether sigma1 receptors are involved in the damaged dopaminergic system in PD patients. MATERIALS AND METHODS: We studied seven normal volunteers and six PD patients. The low density of dopamine transporters and the normal or high density of dopamine receptors were confirmed in the putamen of all patients using [11C]CFT and [11C]RAC PET. A dynamic series of PET data acquisition was performed with arterial blood sampling. We computed the binding potential (BP) of [11C]SA4503. RESULTS: In PD patients, the BP was significantly lower on the more affected than the less affected side of the anterior putamen, although there was no significant difference with respect to the BP between patients and controls. CONCLUSIONS: Release of dopamine is reduced asymmetrically in the putamen of early PD. [11C]SA4503 PET is an indicator of presynaptic dopaminergic damage in PD.
OBJECTIVE: The objective of this study was to investigate the mapping of sigma1 receptors in Parkinson's disease (PD) using [11C]SA4503 and positron emission tomography (PET), and to assess whether sigma1 receptors are involved in the damaged dopaminergic system in PDpatients. MATERIALS AND METHODS: We studied seven normal volunteers and six PDpatients. The low density of dopamine transporters and the normal or high density of dopamine receptors were confirmed in the putamen of all patients using [11C]CFT and [11C]RAC PET. A dynamic series of PET data acquisition was performed with arterial blood sampling. We computed the binding potential (BP) of [11C]SA4503. RESULTS: In PDpatients, the BP was significantly lower on the more affected than the less affected side of the anterior putamen, although there was no significant difference with respect to the BP between patients and controls. CONCLUSIONS: Release of dopamine is reduced asymmetrically in the putamen of early PD. [11C]SA4503 PET is an indicator of presynaptic dopaminergic damage in PD.
Authors: Shang-Yi A Tsai; Michael J Pokrass; Neal R Klauer; Nicole E De Credico; Tsung-Ping Su Journal: Expert Opin Ther Targets Date: 2014-10-21 Impact factor: 6.902
Authors: Nidhi Kaushal; Michael J Seminerio; Matthew J Robson; Christopher R McCurdy; Rae R Matsumoto Journal: Eur Neuropsychopharmacol Date: 2012-08-24 Impact factor: 4.600
Authors: Nidhi Kaushal; Michael J Seminerio; Jamaluddin Shaikh; Mark A Medina; Christophe Mesangeau; Lisa L Wilson; Christopher R McCurdy; Rae R Matsumoto Journal: Neuropharmacology Date: 2011-07-07 Impact factor: 5.250
Authors: Anna A Rybczynska; Philip H Elsinga; Jurgen W Sijbesma; Kiichi Ishiwata; Johan R de Jong; Erik F de Vries; Rudi A Dierckx; Aren van Waarde Journal: Eur J Nucl Med Mol Imaging Date: 2009-02-27 Impact factor: 9.236